Mirati Therapeutics, Inc.
MRTX
Rangering i aksjer
#4928
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Aksjekurs
$58.70
Sist synkronisert: 2024-01-23
Markedsverdi
$2.98B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Mirati Therapeutics, Inc. (MRTX)
Kategori
Healthcare
EPS for Mirati Therapeutics, Inc. (MRTX)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Mirati Therapeutics, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Mirati Therapeutics, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
